Physician profile
Marcus H Bell
NPI 1083934095
$2,691.09
in general payments reported to CMS, 2019-2025
21 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $383 · 2021: $251 · 2022: $289 · 2023: $297 · 2024: $266 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,004.00 | 2019-2023 | Xarelto |
| Pfizer INC. | $594.28 | 2019-2025 | |
| Emd Serono, INC. | $322.19 | 2023-2024 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $136.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.57 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $59.58 | 2019-2020 | |
| Abbvie INC. | $53.76 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $50.72 | 2019-2022 | |
| Melinta Therapeutics, LLC | $43.32 | 2019-2023 | Vabomere, Kimyrsa |
| Amgen INC. | $37.40 | 2020-2022 | |
| Astellas Pharma US INC | $36.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $35.25 | 2023-2024 | Rebyota |
| Edwards Lifesciences Corporation | $27.86 | 2019 | |
| Biomerieux INC | $25.06 | 2019 | |
| Csl Behring | $24.80 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.31 | 2025 | |
| Neurocrine Biosciences, INC. | $22.90 | 2025 | |
| Gilead Sciences, INC. | $22.80 | 2021 | |
| Shire North American Group INC | $16.18 | 2019 | |
| Dexcom, INC. | $15.76 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $13.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.